Alnylam Pharmaceuticals (NASDAQ:ALNY) Emerges as a Decent Value Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY) Emerges as a Decent Value Stock ChartMill
Covered in this story
Analyst targets on Alnylam Pharmaceuticals
- Truist Securities: at $161 · target $225 by Nov 2027 via GuruFocus
- Bernstein: at $165 · target $199 by Oct 2027 via GuruFocus
- Freedom Broker: at $174 · target $350 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 38 stories mentioning Alnylam Pharmaceuticals, the earliest published 20 May 2017.
Summary aggregated from ChartMill's public RSS feed. The full reporting belongs to ChartMill — please read it on their site.